Targeting MCM2 activates cancer-associated fibroblasts-like phenotype and affects chemo-resistance of liposarcoma cells against doxorubicin.

Anticancer Drugs

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China.

Published: November 2024

AI Article Synopsis

  • Liposarcoma is a common type of soft tissue cancer, and previous research showed that the expression of the gene minichromosome maintenance 2 (MCM2) is increased in liposarcoma tissues.
  • The study used various laboratory methods, such as PCR, immunohistochemistry, and assays, to analyze how MCM2 affects liposarcoma cells, including their proliferation, migration, and response to treatment with doxorubicin.
  • Results indicated that high levels of MCM2 enhance the formation of cancer-associated fibroblasts (CAFs) and contribute to tumor growth, suggesting that targeting MCM2 might be a valuable treatment strategy for liposarcoma.

Article Abstract

Liposarcoma is one of the most common soft tissue malignancies. We previously discovered upregulation of minichromosome maintenance 2 (MCM2) expression in liposarcoma tissues. Hereon, we attempt to clarify the biological influence and mechanisms of MCM2 in liposarcoma. The mRNA level of MCM2 expression was detected through the use of quantitative real-time PCR. Immunohistochemistry staining and western blot were employed to detect protein expression of MCM2. The protein expression of fibroblast-activation protein and α-smooth muscle actin was examined by immunofluorescence. Protein concentrations of interleukin (IL)-6, transforming growth factor β, and IL-8 were measured via ELISA. Furthermore, liposarcoma cell viability was assessed through cell counting kit-8 assay, and liposarcoma cell invasiveness and migration were evaluated through transwell assay. For assessing proliferation and apoptosis of liposarcoma cells, colony formation assay and flow cytometry were used. For constructing a mouse tumor model, SW872 cells were introduced into mouse flank via subcutaneous injection. MCM2 expression was boosted in liposarcoma tissues and cells when compared with the controls. MCM2-activated cancer-associated fibroblasts (CAFs)-like phenotype, presenting as increased fibroblast-activation protein expression, α-smooth muscle actin expression, cell migration, IL-6 concentration, IL-8 concentration, and transforming growth factor β concentration. Functional experiments indicated that MCM2-activated-CAFs facilitated proliferation, migration, and invasion of liposarcoma cells. Additionally, 1 μM doxorubicin treatment could not affect proliferation and apoptosis of liposarcoma cells, whereas combined use of MCM2 knockdown and 1 μM doxorubicin evidently repressed cell proliferation and promoted apoptosis. In vivo, silencing of MCM2 impaired tumor growth in mice. MCM2 overexpression promoted CAFs formation and tumor progression, showing potential value in treatment of liposarcoma.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000001641DOI Listing

Publication Analysis

Top Keywords

liposarcoma cells
16
mcm2 expression
12
protein expression
12
liposarcoma
11
mcm2
8
liposarcoma tissues
8
fibroblast-activation protein
8
α-smooth muscle
8
muscle actin
8
transforming growth
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!